Associated Papers
Prostate Ductal Adenocarcinoma Revisited: Clinicopathological and Genomic Characterization Identifies Heterogenous Group of Diseases with Implications for Patient Management.
Cai Q et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2025
SPOP mutations increase PARP inhibitor sensitivity via CK2/PIAS1/SPOP axis in prostate cancer.
Zhang H et al.
Jci Insight, 2025
Opposing Roles of SPOP Mutations in Human Prostate and Endometrial Cancers.
Cavalcante L et al.
Jco Precision Oncology, 2023
SPOP mutations promote tumor immune escape in endometrial cancer via the IRF1-PD-L1 axis.
Gao K et al.
Cell Death and Differentiation, 2023
CHD1, a multifaceted epigenetic remodeler in prostate cancer.
Li H et al.
Frontiers in Oncology, 2023
SPOP inhibits BRAF-dependent tumorigenesis through promoting non-degradative ubiquitination of BRAF.
Feng K et al.
Cell & Bioscience, 2022
SPOP mutations promote p62/SQSTM1-dependent autophagy and Nrf2 activation in prostate cancer.
Shi Q et al.
Cell Death and Differentiation, 2022
Prostate cancer-associated SPOP mutations lead to genomic instability through disruption of the SPOP-HIPK2 axis.
Jin X et al.
Nucleic Acids Research, 2021
Mutated SPOP E3 Ligase Promotes 17βHSD4 Protein Degradation to Drive Androgenesis and Prostate Cancer Progression.
Shi L et al.
Cancer Research, 2021
ATM-phosphorylated SPOP contributes to 53BP1 exclusion from chromatin during DNA replication.
Wang D et al.
Science Advances, 2021
Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly.
Shi Q et al.
Molecular Cancer, 2019
Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid.
Miller AM et al.
Nature, 2019
SPOP promotes ATF2 ubiquitination and degradation to suppress prostate cancer progression.
Ma J et al.
Journal of Experimental & Clinical Cancer Research : Cr, 2018
Somatic Mutation Analyses in Studies of the Clonal Evolution and Diagnostic Targets of Prostate Cancer.
Mikhaylenko DS et al.
Current Genomics, 2017
Dysregulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancer.
Jin X et al.
Plos Genetics, 2017
Next-Generation Sequencing.
Le Gallo M et al.
Advances in Experimental Medicine and Biology, 2017
Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation.
An J et al.
Molecular Cell, 2015
Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer.
Geng C et al.
Cancer Research, 2014
Destruction of DDIT3/CHOP protein by wild-type SPOP but not prostate cancer-associated mutants.
Zhang P et al.
Human Mutation, 2014
Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants.
An J et al.
Cell Reports, 2014
Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover.
Geng C et al.
Proceedings of the National Academy of Sciences of the United States of America, 2013
Speckle-type POZ protein mutations interrupt tumor suppressor function of speckle-type POZ protein in prostate cancer by affecting androgen receptor degradation.
Lai J et al.
Asian Journal of Andrology, 0